- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07654036
Preliminary Evaluation of a Large Language Model-Based Tool for Complex Surgical Decision Support in Lung Cancer
2026. július 29. frissítette: XiuYuan Chen, Peking University People's Hospital
This study is an exploratory effect-size estimation study, with the following specific objectives: ① to estimate the point estimate and 95% confidence interval of the Win Ratio for the experimental group (GAPS-Agent) versus the control group (large language model) in blinded pairwise preference judgments by thoracic surgery expert adjudicators, to serve as a sample size planning parameter for subsequent multicenter confirmatory clinical trials; ② to preliminarily evaluate the value of GAPS-Agent within clinical workflows.The hypothesis of this study is as follows: compared with a general-purpose large language model without medical enhancement (control group), a structured agentic workflow optimized on the basis of the GAPS evaluation framework (GAPS-Agent, experimental group) can help junior resident physicians generate clinical decision plans for complex lung cancer cases that are more strongly preferred by senior thoracic surgery expert adjudicators.
A tanulmány áttekintése
Állapot
Befejezve
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Beavatkozó
Beiratkozás (Tényleges)
8
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.
Tanulmányi helyek
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kína, 100044
- Peking University People's Hospital
-
-
Részvételi kritériumok
A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.
Jogosultsági kritériumok
Tanulmányozható életkorok
- Felnőtt
- Idősebb felnőtt
Egészséges önkénteseket fogad
Nem
Leírás
Inclusion Criteria:
Resident Physician Subjects:
- Holds a valid and legally effective Physician Practice License of the People's Republic of China;
- Currently holds the rank of resident physician in a thoracic surgery department at a tertiary Class A (3A) hospital;
- Agrees to complete all assessment tasks of the main study phase in accordance with the study protocol;
- Can guarantee the time and effort required to complete all assessment tasks of the main study.
Study Cases:
- The case was discussed at the Thoracic Oncology Multidisciplinary Team (MDT) conference of Peking University People's Hospital between January 2025 and May 2026;
- The current version of the NCCN guidelines does not provide an explicit recommendation covering the management of the case;
- Does not overlap with the GAPS evaluation set;
- The case is presented in pure text in a structured format, with all direct and indirect identifiers removed and complete de-identification performed prior to inclusion;
- From the pool of eligible cases, 12 cases will be randomly drawn using Python (numpy.random, with a fixed and archived seed) to serve as the main study cases. The cases will cover 6 themes (chest mass of undetermined diagnosis, early-stage lung cancer, locally advanced lung cancer, oligometastatic/oligoprogressive disease, special intraoperative situations, and tumor recurrence), with 1 - 4 cases per theme.
Adjudication Expert Panel:
- Holds a valid and legally effective Physician Practice License of the People's Republic of China;
- Currently holds the rank of attending physician or above in a thoracic surgery department at a tertiary Class A hospital;
- Chairs or regularly participates in lung cancer multidisciplinary team (MDT) work in their department.
Exclusion Criteria:
Resident Physician Subjects:
- Has previously participated in the construction of the GAPS evaluation set or the development of GAPS-Agent;
- Unable to complete the tasks of the study phase.
Study Cases:
- Key case information is missing, such as text-form data on pathology (including IHC/NGS), imaging, laboratory tests, prior medical history, comorbidities, or PS score;
- Decision-making for the case is strictly dependent on non-text information.
Adjudication Expert Panel:
- Participated in the construction of the GAPS evaluation set, the content validity verification, or the development of GAPS-Agent for this study;
- Has a direct conflict of interest with any specific product among the two-arm tools of this study.
Tanulási terv
Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Egyéb
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Egyetlen
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: test arm
GAPS-Agent
|
The research group has previously developed the GAPS evaluation framework for complex clinical decision-making in lung cancer.
In this framework, G (Grounding) characterizes the cognitive depth of decision-making (ranging from knowledge retrieval to decisions that go beyond clinical guidelines), A (Authority) corresponds to the grading of evidence strength, P (Perturbation) describes the identification and management of real-world clinical confounding factors, and S (Strength) corresponds to the calibration of recommendation strength.
Within this framework, the research group has completed the construction of a 100-item complex lung cancer decision-making evaluation set along with its corresponding rubrics, and has invited multiple thoracic oncology experts to complete content validity validation.
Based on this, the research group developed GAPS-Agent, which uses an open-source large language model as its foundation and integrates functional modules such as guideline and evidence retri
|
|
Aktív összehasonlító: control arm
LLM
|
Open source large language model that is not specifically enhanced in medical field.
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Overall plan Win Ratio
Időkeret: Measured at the time when experts completed their preference judgements. Calculated up to 3 weeks after the preference judgements.
|
A total of 10 blinded expert judges made Win/Tie/Loss ternary preference judgments on 192 paired scheme comparisons in terms of overall scheme quality.
The win ratio was calculated as Wins ÷ Losses, and the 95% confidence interval was estimated using a two-level (physician × case) cluster bootstrap resampling method (B = 10,000, quantile method on the log scale).
|
Measured at the time when experts completed their preference judgements. Calculated up to 3 weeks after the preference judgements.
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Inter-rater agreement
Időkeret: Measured at the time when experts completed their preference judgements. Calculated up to 3 weeks after the preference judgements.
|
For the ternary preference judgment results of 10 expert judges across 192 paired comparisons and 6 evaluation domains, Fleiss' kappa was used to assess inter-rater agreement.
The kappa value and its 95% confidence interval are reported for each evaluation domain.
|
Measured at the time when experts completed their preference judgements. Calculated up to 3 weeks after the preference judgements.
|
|
Redundancy Win Ratio
Időkeret: Measured at the time when experts completed their preference judgements. Calculated up to 3 weeks after the preference judgements.
|
A total of 10 blinded expert judges made Win/Tie/Loss ternary preference judgments on 192 paired scheme comparisons in terms of overall scheme quality.
The win ratio was calculated as Wins ÷ Losses, and the 95% confidence interval was estimated using a two-level (physician × case) cluster bootstrap resampling method (B = 10,000, quantile method on the log scale).
|
Measured at the time when experts completed their preference judgements. Calculated up to 3 weeks after the preference judgements.
|
|
Evidence-based medicine adherence Win Ratio
Időkeret: Measured at the time when experts completed their preference judgements. Calculated up to 3 weeks after the preference judgements.
|
A total of 10 blinded expert judges made Win/Tie/Loss ternary preference judgments on 192 paired scheme comparisons in terms of overall scheme quality.
The win ratio was calculated as Wins ÷ Losses, and the 95% confidence interval was estimated using a two-level (physician × case) cluster bootstrap resampling method (B = 10,000, quantile method on the log scale).
|
Measured at the time when experts completed their preference judgements. Calculated up to 3 weeks after the preference judgements.
|
|
Actionability Win Ratio
Időkeret: Measured at the time when experts completed their preference judgements. Calculated up to 3 weeks after the preference judgements.
|
A total of 10 blinded expert judges made Win/Tie/Loss ternary preference judgments on 192 paired scheme comparisons in terms of overall scheme quality.
The win ratio was calculated as Wins ÷ Losses, and the 95% confidence interval was estimated using a two-level (physician × case) cluster bootstrap resampling method (B = 10,000, quantile method on the log scale).
|
Measured at the time when experts completed their preference judgements. Calculated up to 3 weeks after the preference judgements.
|
|
Completeness Win Ratio
Időkeret: Measured at the time when experts completed their preference judgements. Calculated up to 3 weeks after the preference judgements.
|
A total of 10 blinded expert judges made Win/Tie/Loss ternary preference judgments on 192 paired scheme comparisons in terms of overall scheme quality.
The win ratio was calculated as Wins ÷ Losses, and the 95% confidence interval was estimated using a two-level (physician × case) cluster bootstrap resampling method (B = 10,000, quantile method on the log scale).
|
Measured at the time when experts completed their preference judgements. Calculated up to 3 weeks after the preference judgements.
|
|
Safety Win Ratio
Időkeret: Measured at the time when experts completed their preference judgements. Calculated up to 3 weeks after the preference judgements.
|
A total of 10 blinded expert judges made Win/Tie/Loss ternary preference judgments on 192 paired scheme comparisons in terms of overall scheme quality.
The win ratio was calculated as Wins ÷ Losses, and the 95% confidence interval was estimated using a two-level (physician × case) cluster bootstrap resampling method (B = 10,000, quantile method on the log scale).
|
Measured at the time when experts completed their preference judgements. Calculated up to 3 weeks after the preference judgements.
|
|
GAPS automated rubric score
Időkeret: Generated up to 3 weeks after residents finished their plan generation.
|
A third-party large language model, independent of the two study arms' base models, served as the judge model and automatically scored all 96 plans according to the GAPS rubric.
|
Generated up to 3 weeks after residents finished their plan generation.
|
|
Subject physician's self-confidence score
Időkeret: Completed at the time when residents submitted their plans. Calculated up to 3 weeks after the submission.
|
After submitting each case plan, the participating physicians self-rated their confidence in their own plan using a 1-5 point Likert scale.
|
Completed at the time when residents submitted their plans. Calculated up to 3 weeks after the submission.
|
|
Tool satisfaction score
Időkeret: Completed at the time when residents submitted their plans. Calculated up to 3 weeks after the submission.
|
After submitting each case plan, the participating physicians rated their satisfaction with the tool using a 1-5 point Likert scale.
|
Completed at the time when residents submitted their plans. Calculated up to 3 weeks after the submission.
|
|
Tool trustworthiness score
Időkeret: Completed at the time when residents submitted their plans. Calculated up to 3 weeks after the submission.
|
After submitting each case plan, the participating physicians rated the tool's credibility using a 1-5 point Likert scale.
|
Completed at the time when residents submitted their plans. Calculated up to 3 weeks after the submission.
|
|
Decision-making time
Időkeret: Completed at the time when residents submitted their plans. Calculated up to 3 weeks after the submission.
|
The time taken (in minutes) by each participating physician to complete the production of each case plan was automatically recorded by the evaluation platform.
Differences between groups were analyzed using a linear mixed-effects model.
|
Completed at the time when residents submitted their plans. Calculated up to 3 weeks after the submission.
|
Együttműködők és nyomozók
Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.
Szponzor
Tanulmányi rekorddátumok
Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
2026. június 10.
Elsődleges befejezés (Tényleges)
2026. június 20.
A tanulmány befejezése (Tényleges)
2026. június 21.
Tanulmányi regisztráció dátumai
Először benyújtva
2026. június 10.
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
2026. június 13.
Első közzététel (Tényleges)
2026. június 17.
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
2026. július 30.
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
2026. július 29.
Utolsó ellenőrzés
2026. július 1.
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- 2026PHB458-001
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
NEM
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Nem
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Nem
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .